PE-22-28 Dosage: No Human Dose Has Ever Been Tested
PE-22-28 dosage: no human trial has ever tested this compound. What the one published mouse study used, and why no common human protocol is reported.
The short version
No human being has ever been dosed with PE-22-28 in a published trial, so there is no established human dose. The one published study gave mice 3.2-4.0 mcg per kg by intraperitoneal injection, or 1.0 mg per kg by oral gavage. The one research-market page that quotes a "human range" is extrapolating, not reporting anything measured, and no second source agrees. This page reports no common protocol.
- No human has ever been dosed with PE-22-28 in a published trial, so no human protocol is established.
- The one published mouse study used 3.2-4.0 mcg/kg intraperitoneal, or 1.0 mg/kg oral gavage.
- Only one of four research-market pages gives a human figure, and it contradicts itself in the same paragraph.
- Reconstitution and injection-volume math belongs on a calculator, not a guess. No legitimate dosing target exists here to calculate toward.
No human being has ever been dosed with PE-22-28 in a published trial. This page reports what the one published mouse study used. It also explains why the “human doses” circulating on research-market pages do not meet this site’s bar for a common protocol. For the mechanism and full evidence picture, see the main PE-22-28 guide.
US legal status - Unapproved drug
No FDA-approved product, no registered human trial of any kind, and no dietary-supplement status. Sold as an unregulated research chemical.
PE-22-28 dosage: no common protocol found
Common protocol
No consistent protocol in circulation. No two real sources agree on a usable human protocol, and no human dosing has ever been established by any trial. Of four research-market pages fetched, only one (peptidesinstitute.org) states a human figure at all - an 'investigational human range' of 0.5-2 mg subcutaneous - while in the same breath stating human clinical dosing has not been established and no registered human trials exist. Superpower.com reports only the rodent doses from the one published study (3.2-4.0 mcg/kg intraperitoneal, or 1.0 mg/kg oral gavage in mice) and states explicitly that a PubMed search for 'PE-22-28 human' returns zero results. Myotrope.com and purepeptides.com give no dosing figure of any kind, human or animal. A single unsupported 'investigational' figure, contradicted by its own page and unmatched by any second source, is not a common protocol this site will state.
Only one of the four research-market pages I checked gives a human figure at all, and it undercuts itself in the same paragraph. It states an “investigational human range” while also stating that human clinical dosing has not been established and that no registered human trials exist. The other pages report only the mouse study’s own doses, or nothing at all. No two sources agree on a usable human figure, so this site reports none.
The one published dose: mice, not humans
A study using in vitro channel-binding assays and mouse behavioral testing Djillani 2017 - Djillani A, Pietri M, Moreno S et al. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017;8:643., in the references below is the only published dosing data that exists for PE-22-28:
| Species | Dose | Route | Duration |
|---|---|---|---|
| Mouse | 3.2-4.0 mcg/kg | Intraperitoneal injection | Behavioral testing after acute or 4-day sub-chronic dosing |
| Mouse | 1.0 mg/kg | Oral gavage | Comparable behavioral endpoints |
These are rodent research-protocol doses, assigned by investigators to laboratory animals under controlled conditions. None of the sources this page cites endorses converting a milligram-per-kilogram mouse dose to a human dose by simple bodyweight scaling. This page does not perform that conversion.
How to reconstitute PE-22-28
This page has no legitimate dosing target to help anyone reconstitute toward. The dosage calculator works through general reconstitution arithmetic for a given vial. It does not supply or endorse a dose for a compound with no established human protocol.
What is not established
- No human trial has ever been registered or published for PE-22-28, at any dose, in any population.
- No FDA-approved dose exists, because no product has undergone any regulatory review.
- No common-practice protocol exists in real sources. The one page that states a human figure contradicts itself, and no second source corroborates it.
- Interspecies scaling from the mouse doses above has not been done and published by any source this page cites.
Who should not use it
No FDA-reviewed contraindication list exists, because no human study of any kind has been conducted. Depression is a serious, treatable medical condition. Nobody should substitute an unstudied research chemical, sold outside any regulated supply chain, for evaluation and care from a licensed clinician.
PE-22-28 side effects and risks
The one published mouse study reported no treatment-related toxicity at the doses it tested, over a short 4-day sub-chronic window. That says nothing about a human being, at any dose, over any duration, and no such study exists. A vial sold outside any clinical or regulated system carries no verified content, purity or concentration.
Related
- PE-22-28: what the mouse research actually shows
- Semax dosage
- Selank dosage
- Dosage calculator
- Research peptides and the law
Where to buy PE-22-28 for research
Each vendor is checked against my vendor checklist.
1.Next Level PharmFeatured
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
- Takes card payment
2.BioEdge Research Labs
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
Common questions
What is the usual PE-22-28 dose?
There is no usual dose. I checked four research-market pages. Only one gives a human figure at all (0.5-2 mg subcutaneous). In the same breath it says human dosing has not been established and no registered human trials exist. No second source corroborates that figure, so no common protocol is reported here.
What dose did the mouse study use?
The one published study tested PE-22-28 in mice at 3.2-4.0 micrograms per kilogram by intraperitoneal injection, or 1.0 milligram per kilogram by oral gavage. Dosing ran for 4 days (sub-chronic treatment) before behavioral testing. That is a rodent research-protocol dose. It does not scale to a person by simple bodyweight conversion.
Is there an FDA-approved PE-22-28 dose?
No. PE-22-28 has no FDA-approved product and has never been tested in a registered human trial of any kind. The figures on this page come from a single mouse study's design. They are not a recommended or established dose for anyone.
Why do some websites give a specific human dose?
One page I checked (Peptides Institute) states an "investigational human range" of 0.5-2 mg subcutaneous. In the same breath it says human clinical dosing has not been established and no registered human trials exist for PE-22-28. The figure is an extrapolation presented alongside its own disclaimer, not a measured or trial-derived number. No second source agrees with it.
What are the main risks?
There is no human safety data at all. A vial sold as PE-22-28 is made and sold entirely outside any regulated or clinical-trial supply chain. It carries no verified content, purity or actual concentration.
When should I stop and get medical care?
Get emergency care (call 911 in the US) for any severe or rapidly worsening symptom. Do the same for signs of a severe allergic reaction: swelling of the face, lips, tongue or throat, or difficulty breathing. Call Poison Control at 1-800-222-1222 if you have taken an unknown or excessive amount of anything sold as PE-22-28. This page is not a substitute for a clinician who knows your history.
References (2 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Djillani A, Pietri M, Moreno S et al. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017;8:643.StudyPMID 28955242full text
- 2.America's Poison Centers - confirms 1-800-222-1222 as the national Poison Control number, free and confidential, 24 hours a day.- America's Poison Centersother